Avantor, Inc. · AVTR · FY2026 Q3 · Calendar Q4 2026

Avantor reports stronger growth and raises 2026 outlook

Avantor's Q3 results support a constructive operating trajectory: organic growth returned, VWR accelerated, BMP improved and management raised its outlook. The thesis still depends on sustaining margin expansion while navigating inflation, mix, Europe and BMP order timing.

Why did AVTR fall 2.6% after beating EPS estimates in FY2026 Q3?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNYSEHealthcare $11.29B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $0.22 Consensus $0.21
EPS surprise +5.3% Reported versus consensus
Reported revenue $1.70B Consensus $1.64B
Revenue surprise +3.4% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move -2.6% Event window
SPY move +0.3% Same window
Abnormal move -2.9% Stock minus SPY
Volume 3.2× Versus trailing sessions
Subsequent drift 0.0% Up to 20 sessions
AVTRSPY benchmark

Ask FN2 about AVTR FY2026 Q3

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Compared with the prior quarter, Avantor reported stronger organic growth, with VWR accelerating and BMP returning to positive organic growth. Management also highlighted broader AI and digital-tool adoption, further deleveraging and raised full-year guidance.

Guidance delta

Management raised full-year 2026 organic revenue, adjusted EPS and free-cash-flow guidance, building on the prior quarter's raised outlook.

Key takeaways

  • Q3 revenue was $1.698 billion, with 5.2% organic growth.
  • VWR accelerated to 5.8% organic growth, while BMP returned to positive organic growth.
  • The Revival program, pricing recovery and operational improvements supported momentum.
  • Free cash flow and deleveraging remained priorities as net leverage reached 3.1x.
  • Management is expanding AI, e-commerce and digital-manufacturing capabilities.

Management priorities

  • Execute the Revival program
  • Expand AI tools and e-commerce capabilities
  • Improve manufacturing, supply-chain and S&OP processes
  • Continue deleveraging toward adjusted net leverage below 3x
  • Use the December 8 Investor Day to discuss the long-term financial framework

Follow AVTR with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
AVTR EPS earnings history estimate and actual scatter chart 10 reported fiscal quarters and 4 future estimate-only quarters. Q2 '24 estimate $0.23 Q2 '24 actual $0.25, beat Q3 '24 estimate $0.25 Q3 '24 actual $0.26, match Q2 '25 estimate $0.25 Q2 '25 actual $0.24, match Q3 '25 estimate $0.22 Q3 '25 actual $0.22, match Q4 '25 estimate $0.21 Q4 '25 actual $0.22, match Q1 '26 estimate $0.16 Q1 '26 actual $0.17, beat Q2 '26 estimate $0.19 Q2 '26 actual $0.21, beat Q3 '26 estimate $0.21 Q3 '26 actual $0.22, beat Q4 '26 estimate $0.22 Q1 '27 estimate $0.19 Q2 '27 estimate $0.23 Q3 '27 estimate $0.23
Show 2 more >

Analyst Consensus ?

ConsensusHold25 ratings
Bullish728.0%
Neutral1664.0%
Bearish28.0%

Analyst 52W Price Targets

$14.84Current
$7Low
$20.05Average
$50High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Stifel Hold HoldMaintainOct 29, 2026
RBC Capital Sector Perform Sector PerformMaintainOct 29, 2026
Barclays Underweight UnderweightMaintainOct 29, 2026
Baird Outperform OutperformMaintainOct 29, 2026
TD Cowen Hold HoldMaintainOct 13, 2026
Morgan Stanley Equal Weight Equal WeightMaintainOct 13, 2026
UBS Neutral NeutralMaintainSep 9, 2026
Wells Fargo Overweight OverweightMaintainJul 30, 2026
Evercore ISI Group In Line In LineMaintainJul 30, 2026
Citigroup Neutral NeutralMaintainJul 8, 2026
Jefferies Underperform HoldDowngradeDec 17, 2025
JP Morgan Neutral OverweightDowngradeOct 30, 2025
Raymond James Outperform OutperformMaintainOct 16, 2025
Goldman Sachs Neutral BuyDowngradeApr 29, 2025
Deutsche Bank Hold HoldMaintainApr 18, 2024
William Blair Market Perform OutperformDowngradeJul 31, 2023
Credit Suisse Neutral NeutralMaintainJul 31, 2023
B of A Securities Buy BuyMaintainJul 31, 2023
Keybanc Overweight OverweightMaintainSep 15, 2022
Cowen & Co. Market Perform OutperformDowngradeSep 14, 2022
Cleveland Research Neutral BuyDowngradeSep 9, 2022
Piper Sandler Overweight NeutralUpgradeAug 2, 2021
Stifel Nicolaus Hold HoldMaintainNov 15, 2019
Janney Capital Buy BuyMaintainJun 14, 2019
Piper Jaffray Neutral NeutralMaintainJun 11, 2019
Show less

Named analyst price targets

Upside is calculated against the persisted current price $14.84. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Deutsche BankAnalyst unavailable$17$16.46 +14.6%Oct 29, 2026
Robert W. BairdAnalyst unavailable$18$16.69 +21.3%Oct 29, 2026
BarclaysAnalyst unavailable$16$16.69 +7.8%Oct 29, 2026
Evercore ISIAnalyst unavailable$17$16.69 +14.6%Oct 28, 2026
RBC CapitalDan Leonard$17$16.69 +14.6%Oct 28, 2026
UBSDoug Schenkel$16$15.25 +7.8%Sep 9, 2026
Morgan StanleyAnalyst unavailable$14$13.66 -5.7%Jul 30, 2026
RBC CapitalDan Leonard$14$13.98 -5.7%Jul 30, 2026
Deutsche BankAnalyst unavailable$13$14.06 -12.4%Jul 30, 2026
JefferiesAnalyst unavailable$13$14.38 -12.4%Jul 29, 2026
Evercore ISIAnalyst unavailable$10.5$10.4 -29.2%Jul 6, 2026
BernsteinAnalyst unavailable$10.5$10.08 -29.2%Jun 26, 2026
UBSAnalyst unavailable$8$9.43 -46.1%Jun 24, 2026
Wolfe ResearchAnalyst unavailable$7$9.19 -52.8%Jun 1, 2026
RBC CapitalAnalyst unavailable$9$7.94 -39.4%May 14, 2026
BarclaysAnalyst unavailable$7$8.18 -52.8%Apr 14, 2026
Morgan StanleyAnalyst unavailable$10$9.38 -32.6%Feb 13, 2026
UBSDan Leonard$10.5$9.34 -29.2%Feb 12, 2026
Stifel NicolausAnalyst unavailable$10$9.24 -32.6%Feb 12, 2026
JefferiesTycho Peterson$8$9.24 -46.1%Feb 12, 2026
BarclaysAnalyst unavailable$9$9.64 -39.4%Feb 12, 2026
Robert W. BairdAnalyst unavailable$11$9.64 -25.9%Feb 12, 2026
Evercore ISIVijay Kumar$10$9.32 -32.6%Feb 11, 2026
Evercore ISIAnalyst unavailable$12$11.46 -19.1%Jan 5, 2026
JefferiesTycho Peterson$9$11.2 -39.4%Dec 17, 2025
BarclaysLuke Sergott$12$11.58 -19.1%Oct 30, 2025
UBSAnalyst unavailable$12$11.58 -19.1%Oct 30, 2025
BarclaysLuke Sergott$15$13.67 +1.1%Oct 2, 2025
Stifel NicolausAnalyst unavailable$12$11.3 -19.1%Aug 4, 2025
Raymond JamesAnalyst unavailable$14$11.3 -5.7%Aug 4, 2025
Robert W. BairdAnalyst unavailable$17$12.49 +14.6%Apr 28, 2025
Morgan StanleyTejas Savant$15$12.93 +1.1%Apr 28, 2025
BarclaysLuke Sergott$26$21.87 +75.2%Feb 3, 2025
BernsteinEve Burstein$24.5$21.66 +65.1%Jan 10, 2025
Evercore ISIVijay Kumar$26$21.2 +75.2%Jan 2, 2025
Robert W. BairdCatherine Schulte$26$22.56 +75.2%Oct 28, 2024
Morgan StanleyTejas Savant$28$24.4 +88.7%Oct 21, 2024
Robert W. BairdCatherine Schulte$27$26.02 +81.9%Jul 29, 2024
Evercore ISIVijay Kumar$27.5$25.6 +85.3%Jul 26, 2024
Evercore ISIVijay Kumar$27$20.77 +81.9%Jul 2, 2024
JefferiesTycho Peterson$28$24.08 +88.7%Jun 3, 2024
Deutsche BankJustin Bowers$25$24.38 +68.5%Apr 18, 2024
Raymond JamesAndrew Cooper$30$23.05 +102.2%Feb 5, 2023
Raymond JamesAndrew Cooper$36$28.34 +142.6%Aug 9, 2022
Robert W. BairdCatherine Schulte$34$28.34 +129.1%Aug 8, 2022
BarclaysLuke Sergott$33$28.67 +122.4%Aug 4, 2022
Wells FargoAnalyst unavailable$33$29.95 +122.4%Apr 25, 2022
Stifel NicolausDaniel Arias$46$42.33 +210.0%Sep 10, 2021
Credit SuisseKatie Tryhane$50$42.33 +236.9%Sep 10, 2021
GuggenheimSandy Draper$45$37.6 +203.2%Aug 2, 2021
Morgan StanleyTejas Savant$44$37.6 +196.5%Aug 2, 2021
Goldman SachsMatthew Sykes$40$31.3 +169.5%Jun 4, 2021
Show less

Track every rating change on AVTR the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company's extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone materials, tailored excipients, single-use assemblies, process chromatography resins and columns, analytical sample…

Historical context

All AVTR earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the AVTR recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-10-28T14:05:15.608732+00:00
  2. FN2 earnings calendar · 2026-10-29T01:23:20.584741+00:00
  3. Polygon adjusted daily market bars · 2026-10-29T03:40:43.174153+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-29T03:40:43.171270+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-29. For educational purposes only; not investment advice.